Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now
featured
Published in Metastatic Breast Cancer

Journal Scan / Research · February 15, 2021

Pertuzumab-Associated Diarrhoea and Rash Predict Survival Outcomes in Patients With HER2+ Metastatic Breast Cancer

European Journal of Cancer

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Lillie Shockney RN, BS, MAS, HON-ONN-CG

European Journal of Cancer
Association Between Pertuzumab-Associated Diarrhoea and Rash and Survival Outcomes in Patients With HER2-Positive Metastatic Breast Cancer: Exploratory Analysis From the CLEOPATRA Trial
Eur. J. Cancer 2021 Feb 01;144(xx)351-359, A R Ferreira, S Ferreira, M Lambertini, C Maurer, S Martel, L Costa, N Ponde, E de Azambuja

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated